Table 2. Drug-induced activation of TCRα Skw3 transductants.

Skw3 cell lines engineered for the expression of TCRs bearing Vα and Vβ chains from top clones found in patients TEN-3, TEN-7, TEN-10, and TEN-15 were stimulated in vitro with EBV-transformed B cells in the presence of graded doses of different drugs or left unpulsed. This depicts the percentage of CD69 expression in CD3⁺ transductants measured by FACS after 24 hours of stimulation. Results from control transductants generated from abacavir-allergic (17D), allopurinol-allergic (AnWe A1), or sulfamethoxazole-allergic (UNO H13) donors (7, 52, 54) are also shown. Bold and underlined values indicate >2 or >1.5 CD69 expression fold increase versus unpulsed cultures. Transductant IDs are from table S12. Autologous EBV-transformed B cells were used for all the patients, except for patient TEN-7, for whom we did not have any autologous PBMCs available; hence, we performed the same analysis with heterologous PBMCs from different healthy donors. Heterologous EBV-transformed B cells were also used to stimulate control transductants.

			% of CD69 expression in CD3+ transfectants
Patient ID	Skw3 transfectant ID	Drug concentrations (μg/ml)	No drug	Concentration 1	Concentration 2	Concentration 3
TEN-3	C1	Allopurinol (62.5/250)	2.3		2.2	3.05
		Oxypurinol (62.5/250)	2.3		22.9	39.6
		Sulfamethoxazole (100/200)	2.3		1.3	1.4
TEN-7	C2	Pantoprazole (10/50)	31.7		40.1	47.4
TEN-10	C3	Ceftriaxone (50/100/200)	12.2	11.9	12	13.8
		Ciprofloxacin (12.5/25/50)	10.9	10.1	11.8	10.6
TEN-15	C4	Levofloxacin (25/50/100)	6	5.6	5.4	4.4
		Metronidazole (25/50/100)	6.3	5.7	5.4	6
Control-1	17D	Abacavir (1/10/20)	1.4	93.2	88.9	93.1
		Pantoprazole (12.5/25/50)	1.4	1.8	1.8	1.7
Control-2	AnWe A1	Allopurinol (62.5/250)	4.3		17.1	26.4
		Oxypurinol (62.5/250)	4.3		5	5.75
Control-3	UNO H13	Ibuprofen (20/100/200)	5.2	4.6	10.5	12.4